Eli Lilly Reports Strong Q3 2026 Results Driven by Mounjaro and Zepbound Demand
Eli Lilly (LLY) reported robust third-quarter 2026 financial results, with revenue reaching $24.4 billion, a 39% increase year-over-year. This growth was primarily fueled by the massive expansion of its incretin portfolio, specifically Mounjaro and Zepbound, which saw revenues of $10.7 billion and $5.3 billion respectively. The company also raised its full-year 2026 revenue guidance to a range of $91 billion to $92 billion. Beyond current sales, Lilly demonstrated significant pipeline momentum with positive Phase 3 results for Retatrutide and strong uptake of Kisunla in the amyloid targeting market. To support this rapid scaling, the company has broken ground on $11.5 billion in new U.S. manufacturing facilities. Despite a 10% decline in U.S. pricing due to competitive dynamics, improved manufacturing efficiencies helped push non-GAAP gross margins to 84.4%.
Tickers: $LLY
Topics: Financial Guidance GLP-1 Drugs Pharmaceuticals Revenue Growth Weight Management Market